Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib with Rituximab and Chemotherapy in Newly Diagnosed Aggressive B-NHL
NCT05097443Phase 3Unknown
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in B-cell non-Hodgkin lymphoma, sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Status: unknown.
02
Drugs
orelabrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05097443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097443.